Smart, Andrew (Author)
Martin, Paul C. (Author)
Pharmacogenetics is an emerging biotechnology concerned with understanding the genetic basis of drug response, and promises to transform the development, marketing and prescription of medicines. This paper is concerned with analysing the move towards segmented drug markets, which is implicit in the commercial development of pharmacogenetics. It is claimed that in future who gets a particular drug will be determined by their genetic make up. Drawing on ideas from the sociology of expectations we examine how pharmaceutical and biotechnology companies are constructing, responding to and realising particular `visions' or expectations of pharmacogenetics and market stratification. We argue that the process of market segmentation remains uncertain, but that the outcome will be fashioned according to the convergence and divergence of the interests of key commercial actors. Qualitative data based both on interviews with industry executives and company documentation will be used to explore how different groups of companies are developing pharmacogenetics in distinct ways, and what consequences these different pathways might have for both clinical practice and health policy. In particular, the analysis will show a convergence of interests between biotechnology and pharmaceutical companies for creating segmented markets for new drugs, but a divergence of interest in segmenting established markets. Whilst biotechnology firms have a strong incentive to innovate, the pharmaceutical industry has no commercial interest in segmenting markets for existing products. This has important implications, as many of the claimed public health benefits of pharmacogenetics will derive from changing the prescribing of existing medicines. One significant implication of this is that biotechnology companies who wish to apply pharmacogenetics to existing medicines will have to explore an alternative convergence of interests with healthcare payers and providers (health insurers, HMOs, MCOs and national health systems). Healthcare providers may have a strong incentive to use pharmacogenetics to make the prescribing of existing medicine more cost-effective. However, we conclude by suggesting that a question mark hangs over their ability to provide the necessary economic and structural resources to bring such a vision to fruition.
...MoreArticle Ashcroft, Richard E.; Hedgecoe, Adam M. (2006) Genetic Databases and Pharmacogenetics: Introduction. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences (p. 499).
Article
Hedgecoe, Adam M.;
(2006)
Context, Ethics and Pharmacogenetics
(/isis/citation/CBB000770742/)
Article
Corrigan, Oonagh P.;
Williams-Jones, Bryn;
(2006)
Pharmacogenetics: The Bioethical Problem of DNA Investment Banking
(/isis/citation/CBB000770741/)
Article
Ashcroft, Richard E.;
Hedgecoe, Adam M.;
(2006)
Genetic Databases and Pharmacogenetics: Introduction
(/isis/citation/CBB000770737/)
Book
Hedgecoe, Adam;
(2004)
The Politics of Personalised Medicine: Pharmacogenetics in the Clinic
(/isis/citation/CBB000830804/)
Essay Review
Gaudillière, Jean-Paul;
(2001)
The pharmaceutical industry in the biotech century: Toward a history of science, technology and business?
(/isis/citation/CBB000100750/)
Article
Yi, Doogab;
(2009)
The Scientific Commons in the Marketplace: The Industrialization of Biomedical Materials at the New England Enzyme Center, 1963--1980
(/isis/citation/CBB000931983/)
Book
Hughes, Sally Smith;
(2011)
Genentech: The Beginnings of Biotech
(/isis/citation/CBB001221219/)
Thesis
Jones, Mark Peter;
(2005)
Biotech's Perfect Climate: The Hybritech Story
(/isis/citation/CBB001560595/)
Book
O'Neill, Onora;
(2002)
Autonomy and Trust in Bioethics
(/isis/citation/CBB000771273/)
Article
Schondelmeyer, Stephen W.;
(2009)
Recent Economic Trends in American Pharmacy
(/isis/citation/CBB000933448/)
Article
Herzberg, David;
(2011)
Blockbusters and Controlled Substances: Miltown, Quaalude, and Consumer Demand for Drugs in Postwar America
(/isis/citation/CBB001221531/)
Article
Greene, Jeremy A.;
(2011)
What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine
(/isis/citation/CBB001230383/)
Article
Alan Mackintosh;
(2016)
The Patent Medicines Industry in Late Georgian England: A Respectable Alternative to both Regular Medicine and Irregular Practice
(/isis/citation/CBB566583777/)
Article
Joseph M. Gabriel;
Bennett Holman;
(2020)
Clinical trials and the origins of pharmaceutical fraud: Parke, Davis & Company, virtue epistemology, and the history of the fundamental antagonism
(/isis/citation/CBB230893683/)
Article
Waldby, Catherine;
(2009)
Singapore Biopolis: Bare Life in the City-State
(/isis/citation/CBB000932553/)
Article
Strasser, Bruno J.;
(2011)
The Experimenter's Museum: GenBank, Natural History, and the Moral Economies of Biomedicine
(/isis/citation/CBB001022861/)
Article
Hansson, Mats G.;
(2006)
Combining Efficiency and Concerns about Integrity When Using Human Biobanks
(/isis/citation/CBB000770739/)
Article
Mohácsi, Gergely;
(2013)
The Adiponectin Assemblage: An Anthropological Perspective on Pharmacogenomics in Japan
(/isis/citation/CBB001213613/)
Article
Kahn, Jonathan;
(2008)
Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics
(/isis/citation/CBB000953517/)
Article
Gerald, Michael C.;
(2010)
The Rise and Fall of Celebrity Promotion of Prescription Products in Direct-to-Consumer Advertising
(/isis/citation/CBB001000205/)
Be the first to comment!